G.Research lowered shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a buy rating to a hold rating in a report issued on Friday, Stock Target Advisor reports.

TTPH has been the subject of several other research reports. ValuEngine raised shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, November 1st. Gabelli downgraded shares of Tetraphase Pharmaceuticals from a buy rating to a hold rating in a research note on Friday. HC Wainwright reiterated a hold rating on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Tetraphase Pharmaceuticals has an average rating of Hold and an average target price of $57.00.

Shares of TTPH stock opened at $2.38 on Friday. Tetraphase Pharmaceuticals has a one year low of $1.99 and a one year high of $29.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.49 and a current ratio of 2.70. The company has a 50 day moving average price of $2.64 and a 200 day moving average price of $2.07. The firm has a market capitalization of $8.85 million, a price-to-earnings ratio of -0.08 and a beta of 2.35.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($6.00) EPS for the quarter, topping the consensus estimate of ($6.27) by $0.27. Tetraphase Pharmaceuticals had a negative net margin of 804.43% and a negative return on equity of 152.06%. The firm had revenue of $3.34 million during the quarter, compared to analyst estimates of $1.55 million. As a group, equities analysts forecast that Tetraphase Pharmaceuticals will post -26.51 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in Tetraphase Pharmaceuticals by 803.7% during the second quarter. JPMorgan Chase & Co. now owns 116,428 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 103,544 shares during the period. Paloma Partners Management Co purchased a new stake in Tetraphase Pharmaceuticals during the second quarter worth approximately $115,000. Jane Street Group LLC purchased a new stake in Tetraphase Pharmaceuticals during the second quarter worth approximately $122,000. Vanguard Group Inc. grew its stake in Tetraphase Pharmaceuticals by 7.4% during the second quarter. Vanguard Group Inc. now owns 2,514,773 shares of the biopharmaceutical company’s stock worth $1,208,000 after buying an additional 173,053 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Tetraphase Pharmaceuticals by 17.3% during the second quarter. Renaissance Technologies LLC now owns 2,613,230 shares of the biopharmaceutical company’s stock worth $1,255,000 after buying an additional 386,045 shares during the period. Institutional investors own 16.78% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Read More: What is the Gross Domestic Product (GDP)?

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.